Overview

Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is intended to establish the lowest effective dose of EstroGel® for the treatment of vasomotor symptoms associated with menopause.
Phase:
Phase 4
Details
Lead Sponsor:
ASCEND Therapeutics
Collaborator:
Solvay Pharmaceuticals
Treatments:
Estradiol